AI-generated summary
The authors pooled 18 randomized controlled trials involving 1144 patients with cancer or undergoing stem cell transplantation to compare prophylactic low level laser therapy with placebo or no therapy. They report that laser therapy was associated with a lower risk of severe oral mucositis and severe pain, with random effects models used throughout. The authors note that optimal laser characteristics and clinical feasibility still need to be determined.
- Participants
- 1,144
- Studies included
- 18
- Who or what was studied
- Patients with cancer or undergoing hematopoietic stem cell transplantation
- Limits stated in the abstract
- The abstract does not report wavelengths, doses or the certainty of the evidence, and it states that optimal laser characteristics and feasibility remain to be determined.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Objective was to determine whether prophylactic low level laser therapy (LLLT) reduces the risk of severe mucositis as compared to placebo or no therapy.
Methods
MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched until February 2014 for randomized controlled trials (RCTs) comparing prophylactic LLLT with placebo or no therapy in patients with cancer or undergoing hematopoietic stem cell transplantation (HSCT). All analyses used random effects models.
Results
Eighteen RCTs (1144 patients) were included. Prophylactic LLLT reduced the overall risk of severe mucositis (risk ratio (RR) 0.37, 95% confidence interval (CI) 0.20 to 0.67; P = 0.001). LLLT also reduced the following outcomes when compared to placebo/no therapy: severe mucositis at the time of anticipated maximal mucositis (RR 0.34, 95% CI 0.20 to 0.59), overall mean grade of mucositis (standardized mean difference -1.49, 95% CI -2.02 to -0.95), duration of severe mucositis (weighted mean difference -5.32, 95% CI -9.45 to -1.19) and incidence of severe pain (RR 0.26, 95% CI 0.18 to 0.37).
Conclusion
Prophylactic LLLT reduced severe mucositis and pain in patients with cancer and HSCT recipients. Future research should identify the optimal characteristics of LLLT and determine feasibility in the clinical setting.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Systematic review, Oral mucositis, Meta-analysis, Confidence interval, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.